On October 7, 2019 Vaccibody AS reported that preliminary safety, efficacy and immunogenicity data will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2019 which will be held from November 6-10, 2019 in National Harbor, Maryland (Press release, Vaccibody, OCT 7, 2019, View Source [SID1234540088]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited that our abstract presenting Vaccibody’s preliminary VB10.NEO clinical read-outs has been accepted for poster presentation at this year’s SITC (Free SITC Whitepaper) Meeting," said Michael Engsig, CEO of Vaccibody. The poster will be the first presentation to report clinical data from our VB10.NEO cancer neoantigen study and is an important milestone for the company.

Details of the poster presentation:

Title: Preliminary safety, efficacy and immunogenicity results from a phase 1/2a study (DIRECT-01) of cancer neoantigen DNA vaccine VB10.NEO in patients with locally advanced or metastatic solid tumors

Abstract ID: P424

Session Date and Time: Saturday, November 9 th 2019, 7:00 am-8:30 pm local time

About VB10.NEO
VB10.NEO, is a proprietary therapeutic DNA vaccine which uses the patient’s own neoantigens for the personalized treatment of cancer patients. A phase I/IIa neoantigen clinical trial is currently enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial cancer or squamous cell carcinoma of the head and neck.